Behavioral toxicity of anticholinesterases in primates: chronic physostigmine and soman interactions.
Dose rates for continuous infusion of physostigmine salicylate required to inhibit 30 and 60% of normal serum cholinesterase activity in rhesus monkeys were determined. The effects of continuous physostigmine infusion at these dose rates on the behavioral toxicity of daily repeated low-dose soman were determined not to be deleterious; in fact, they were slightly (and variably) protective.
Blick
D W
DW
Systems Research Laboratories Division of Arvin/Calspan, USAF Armstrong Laboratory, Brooks AFB, TX 78235-5000.
Miller
S A
SA
Brown
G C
GC
Murphy
M R
MR
D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D002800:Cholinesterase Inhibitors / Q000633:toxicity*; D002802:Cholinesterases / Q000097:blood; D004347:Drug Interactions; D007279:Injections, Subcutaneous; D008253:Macaca mulatta; D008297:Male; D010830:Physostigmine / Q000008:administration & dosage / Q000037:antagonists & inhibitors / Q000633:toxicity*; D011597:Psychomotor Performance / Q000187:drug effects; D011729:Pyridostigmine Bromide / Q000494:pharmacology; D012999:Soman / Q000037:antagonists & inhibitors / Q000633:toxicity*
D002800:Cholinesterase Inhibitors; D012999:Soman; D010830:Physostigmine; D002802:Cholinesterases; D011729:Pyridostigmine Bromide